Income Taxes (Tables)

12 Months Ended

Dec. 31, 2014

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

Income taxes for the years ended December 31, 2014 and 2013 differed from the amount computed by applying the U.S. federal income tax rate of 34% to pre-tax loss as a result of the following:

	Years ended December 31,
	2014		2013

	(in thousands)
Computed “expected” income tax benefit	$	(3,761)	$	(2,998)
Increase (decrease) in income taxes resulting from:
2013 pre-Separation losses remaining with Harvard Bioscience		-		2,327
Foreign tax rate and regulation differential		40		13
State income tax benefit, net of federal income tax benefit		(663)		(118)
Non-deductible stock-based compensation expense		94		18
Tax credits		(178)		(50)
Change in valuation allowance allocated to income tax expense		4,468		808
Total income taxes	$	-	$	-

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

The Company has incurred pre-tax losses for the years ended December 31, 2014 and 2013:

	Years ended December 31,
	2014		2013

	(in thousands)
Domestic	$	(10,780)	$	(8,602)
Foreign		(281)		(215)
Total	$	(11,061)	$	(8,817)

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

The components of HART’s deferred tax asset are as follows:

	Years ended December 31,
	2014		2013
	(in thousands)
Deferred tax assets:
Operating loss and credit carryforwards	$	2,543	$	514
Capitalized research and development		1,612		-
Stock-based compensation		1,086		294
Accrued expenses		27		-
Property, plant and equipment		9		-
Total deferred tax assets		5,277		808
Less: valuation allowance		(5,277)		(808)
Deferred tax assets, net	$	-	$	-